JP4435325B2 - 置換三環式化合物およびそれを含有する組成物 - Google Patents

置換三環式化合物およびそれを含有する組成物 Download PDF

Info

Publication number
JP4435325B2
JP4435325B2 JP10965699A JP10965699A JP4435325B2 JP 4435325 B2 JP4435325 B2 JP 4435325B2 JP 10965699 A JP10965699 A JP 10965699A JP 10965699 A JP10965699 A JP 10965699A JP 4435325 B2 JP4435325 B2 JP 4435325B2
Authority
JP
Japan
Prior art keywords
mmol
alkyl
phenyl
benzyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP10965699A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11322745A5 (enExample
JPH11322745A (ja
Inventor
ニコラス・ジェイムズ・バック
ジョリー・アン・バスティアン
ダグラス・ウェイド・ベイト
マイケル・ディーン・キニック
マイケル・ジョン・マルティネリ
エドワード・デイビッド・ミヘリッチ
ジョン・マイケル・モリン・ジュニア
ダニエル・ジョン・サル
ジェイソン・スコット・ソーヤー
エドワード・シー・アール・スミス
テュリオ・スアレス
チウピン・ワン
トーマス・マイケル・ウィルソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of JPH11322745A publication Critical patent/JPH11322745A/ja
Publication of JPH11322745A5 publication Critical patent/JPH11322745A5/ja
Application granted granted Critical
Publication of JP4435325B2 publication Critical patent/JP4435325B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
JP10965699A 1998-04-17 1999-04-16 置換三環式化合物およびそれを含有する組成物 Expired - Fee Related JP4435325B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6216598A 1998-04-17 1998-04-17
US09/062165 1998-04-17

Publications (3)

Publication Number Publication Date
JPH11322745A JPH11322745A (ja) 1999-11-24
JPH11322745A5 JPH11322745A5 (enExample) 2007-04-05
JP4435325B2 true JP4435325B2 (ja) 2010-03-17

Family

ID=22040624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10965699A Expired - Fee Related JP4435325B2 (ja) 1998-04-17 1999-04-16 置換三環式化合物およびそれを含有する組成物

Country Status (27)

Country Link
EP (2) EP0950661B1 (enExample)
JP (1) JP4435325B2 (enExample)
KR (1) KR19990083234A (enExample)
CN (1) CN1235968A (enExample)
AR (1) AR018185A1 (enExample)
AT (2) ATE254128T1 (enExample)
AU (1) AU757454B2 (enExample)
BR (1) BR9901275A (enExample)
CA (1) CA2269256A1 (enExample)
CO (1) CO5080728A1 (enExample)
CZ (1) CZ137199A3 (enExample)
DE (2) DE69912670T2 (enExample)
EA (1) EA003129B1 (enExample)
ES (2) ES2210979T3 (enExample)
HU (1) HUP9901219A1 (enExample)
ID (1) ID23219A (enExample)
IL (1) IL129484A0 (enExample)
NO (1) NO991823L (enExample)
NZ (1) NZ335252A (enExample)
PE (1) PE20000472A1 (enExample)
PL (1) PL332564A1 (enExample)
SG (1) SG106035A1 (enExample)
SV (1) SV1999000052A (enExample)
TR (1) TR199900842A2 (enExample)
TW (1) TW555760B (enExample)
YU (1) YU19099A (enExample)
ZA (1) ZA992773B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610728B2 (en) * 1997-08-28 2003-08-26 Eli Lilly And Company Method for treatment of non-rheumatoid arthritis
AU2001244635A1 (en) * 2000-03-30 2001-10-15 Yamanouchi Pharmaceutical Co..Ltd. Hydrazide derivatives
CN1450893A (zh) * 2000-07-14 2003-10-22 伊莱利利公司 治疗脓毒症的方法
ES2264708T3 (es) * 2000-12-18 2007-01-16 Eli Lilly And Company Derivados tetraciclicos como inhibidores de la spla2.
DE60218155D1 (de) 2001-03-28 2007-03-29 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
JP2005527466A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプトＢインドール誘導体
JP2005527464A (ja) * 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体
US6992100B2 (en) 2001-12-06 2006-01-31 Eli Lilly And Company sPLA2 inhibitors
BRPI0517955A (pt) 2004-11-01 2008-10-21 Wyeth Corp indolizinas substituìdas e derivados como agentes de snc
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
WO2012140612A1 (en) * 2011-04-14 2012-10-18 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
SG11201405328SA (en) 2012-03-16 2014-11-27 Vitae Pharmaceuticals Inc Liver x receptor modulators
ES2607113T3 (es) 2012-03-16 2017-03-29 Vitae Pharmaceuticals, Inc. Moduladores de los receptores X del hígado

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
US6645976B1 (en) * 1994-07-21 2003-11-11 Eli Lilly And Company Indolizine SPLA2inhibitors
DE69614232T2 (de) * 1995-12-13 2002-01-10 Eli Lilly And Co., Indianapolis Naphthyl-Acetamide als sPLA2-Inhibitoren
KR20000049210A (ko) * 1996-10-30 2000-07-25 피터 지. 스트링거 치환된 트리시클릭류
AU9664198A (en) * 1997-09-26 1999-04-23 Eli Lilly And Company Method for the treatment of cystic fibrosis
JP2001522884A (ja) * 1997-11-14 2001-11-20 イーライ・リリー・アンド・カンパニー アルツハイマー病の処置方法

Also Published As

Publication number Publication date
EP1156050B1 (en) 2004-02-18
SG106035A1 (en) 2004-09-30
EP1156050A3 (en) 2001-11-28
NO991823D0 (no) 1999-04-16
EP0950661B1 (en) 2003-11-12
HU9901219D0 (en) 1999-06-28
EP0950661A1 (en) 1999-10-20
ID23219A (id) 2000-03-30
DE69912670D1 (de) 2003-12-18
EA199900304A2 (ru) 1999-10-28
AU2381899A (en) 1999-10-28
ZA992773B (en) 2002-07-16
YU19099A (sh) 2001-09-28
CO5080728A1 (es) 2001-09-25
TW555760B (en) 2003-10-01
KR19990083234A (ko) 1999-11-25
HUP9901219A1 (hu) 2000-08-28
AU757454B2 (en) 2003-02-20
CN1235968A (zh) 1999-11-24
BR9901275A (pt) 2000-05-02
ES2213668T3 (es) 2004-09-01
IL129484A0 (en) 2000-02-29
EP1156050A2 (en) 2001-11-21
NZ335252A (en) 2000-11-24
EA003129B1 (ru) 2003-02-27
EA199900304A3 (ru) 2000-04-24
ES2210979T3 (es) 2004-07-01
PE20000472A1 (es) 2000-06-02
DE69914951D1 (de) 2004-03-25
CA2269256A1 (en) 1999-10-17
AR018185A1 (es) 2001-10-31
PL332564A1 (en) 1999-10-25
ATE254128T1 (de) 2003-11-15
JPH11322745A (ja) 1999-11-24
DE69912670T2 (de) 2004-08-12
CZ137199A3 (cs) 1999-11-17
ATE259818T1 (de) 2004-03-15
SV1999000052A (es) 2000-03-14
DE69914951T2 (de) 2004-12-23
NO991823L (no) 1999-10-18
TR199900842A2 (xx) 2000-09-21

Similar Documents

Publication Publication Date Title
US6177440B1 (en) Substituted tricyclics
AU753547B2 (en) Substituted tricyclics
JP2001503055A5 (enExample)
US6974831B2 (en) sPLA2 inhibitors
EP1156050B1 (en) Substituted tricyclics useful in sPLA2 induced diseases
JP2001503055A (ja) 置換三環化合物群
JP2002522386A (ja) インドールｓＰＬＡ２インヒビター
US20050026988A1 (en) Cyclopenta'b! indole derivatives as spla inhibitors
US6713645B1 (en) Substituted tricyclics
JP2002522385A (ja) インドールｓＰＬＡ２インヒビター
EP1140943B1 (en) Substituted pyrroloindoles
US20040198801A1 (en) Cyclohept'b!indole derivatives as spla2 inhibitors
US6933313B2 (en) Substituted carbazoles as inhibitors of sPLA2
HK1025091A (en) Substituted tricyclics useful in spla2 induced diseases
MXPA99003588A (en) Triciclic composites substitui
US6916840B2 (en) Spla2 inhibitors
HK1024911A (en) Substituted carbazoles, process for their preparation and their use as spla2 inhibitors
MXPA99003587A (es) Compuestos triciclicos substituidos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060417

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20061219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091215

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091224

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130108

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees